Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease

Authors

Alberto Mussetti (ORCID: https://orcid.org/0000-0002-4088-036X)
Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
F Molina

Institutions

Institut Català d'Oncologia (ES)

Publication Details

Journal: Haematologica
Published: 2025-09-25
DOI: https://doi.org/10.3324/haematol.2025.288307
Primary Topic: Acute Myeloid Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Sanofi
Gilead Sciences
Celgene

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease

Alberto Mussetti, Anna Sureda, F Molina

Sep 25, 2025

Haematologica

Acute Myeloid Leukemia Research

article

Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease

Alberto Mussetti, Anna Sureda, F Molina

September 25, 2025article en

Abstract

No abstract available for this paper.

HaematologicaVol. 111(1)

Institut Català d'Oncologia (ES)

Amgen, Sanofi, Gilead Sciences, Celgene

Openalex Percentile: Top 66%

Acute Myeloid Leukemia Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease — Alberto Mussetti, Anna Sureda, et al. · Haematologica (2025) | TGRS Research Map | TGRS